Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atara Biotherapeutics, Inc.

< Previous 1 2 3 4 Next >
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.